Loading
AI
Athersys, INC / NEW Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 22 Nov 2022.
Athersys, INC / NEW: what insiders have been doing
Athersys, INC / NEW, founded in 1995, is a Healthcare & Pharma company based in Cleveland, United States. Its directors and officers file their transactions with SEC (Form 4). No insider at Athersys, INC / NEW has published a filing in the past twelve months. The most recent one dates from 21 December 2023.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: Cleveland, United States · Founded: 1995 · 83 employees (2019)
Source: Wikidata (CC0).
Insider Decl.
48
Thresholds
n/a
Buy Volume
€233,924
4 ops. · all time
Sell Volume
€94,180
3 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$4.6M
Net income-US$62.5M-1362.1% margin
Last declaration on 21 December 2023
Declarations48 total
67 shares@ US$0.0250.0% of flowCommon StockSEC:0001437749-23-035051:0
19,993 shares@ US$0.444.0% of flowCommon StockSEC:0001437749-23-027868:0
23,149 shares@ US$0.4433.1% of flowCommon StockSEC:0001437749-23-027870:0
67 shares@ US$0.300.1% of flowCommon StockSEC:0001437749-23-026268:0
19,993 shares@ US$0.9148.1% of flowCommon StockSEC:0001368148-23-000069:0
7,026 shares@ US$0.91420.2% of flowCommon StockSEC:0001368148-23-000067:0
270 shares@ US$0.930.8% of flowCommon StockSEC:0001368148-23-000059:0
7,366 shares@ US$1.0022.9% of flowCommon StockSEC:0001368148-23-000033:0
19,993 shares@ US$1.008.7% of flowCommon StockSEC:0001368148-23-000031:0
22,321 shares0Common StockSEC:0001368148-23-000017:0
22,321 shares0Common StockSEC:0001368148-23-000015:0
21,951 shares0Common StockSEC:0001368148-23-000013:0
35,714 shares0Common StockSEC:0001368148-23-000019:0
8,253 shares@ US$0.8522.7% of flowCommon StockSEC:0001368148-23-000005:0
23,484 shares@ US$0.859.1% of flowCommon StockSEC:0001368148-23-000007:0
67 shares@ US$0.810.2% of flowCommon StockSEC:0001368148-22-000159:0
100,000 shares@ US$0.549625.7% of flowCommon StockSEC:0001368148-22-000157:0
Canonical exit: 20 Feb 2023 (T+90)
92,593 shares0Common StockSEC:0000899243-22-033110:0
263,492 shares0Common StockSEC:0000899243-22-033112:0
12 shares@ US$1.610.1% of flowCommon StockSEC:0001368148-22-000139:0
12,820 shares0Common StockSEC:0001368148-22-000137:0
12,820 shares0Common StockSEC:0001368148-22-000135:0
12,820 shares0Common StockSEC:0001368148-22-000131:0
20,512 shares0Common StockSEC:0001368148-22-000133:0
33,333 shares0Common StockSEC:0001368148-22-000085:0
25 of 48 declarations
About Athersys, INC / NEW
Athersys, Inc. (NASDAQ: ATHX) is a United States-based biotechnology company listed on the NASDAQ market, with headquarters in Cleveland, Ohio. The company was established in October 1995 and has built its strategy around regenerative medicine and off-the-shelf cell therapy. Its core asset is MultiStem®, an allogeneic, proprietary adult stem-cell product that Athersys is developing to address serious diseases with limited treatment options. In recent company materials, the therapy is also referenced under the name invimestrocel in certain contexts. ([athersys.com](https://www.athersys.com/our-company/overview/default.aspx?LanguageId=1&utm_source=openai))
Athersys is best understood as a clinical-stage biopharmaceutical company rather than a commercial-stage biotech. Its pipeline is concentrated in neurological, inflammatory and immune, cardiovascular, and critical-care indications. The company describes MultiStem as a platform with immunomodulatory and tissue-repair properties, aiming to reduce inflammation, protect injured tissue, and support healing. Its most visible programs have historically included ischemic stroke, acute respiratory distress syndrome (ARDS), severe trauma, and acute myocardial infarction. ([athersys.com](https://www.athersys.com/multistem-therapy/default.aspx?utm_source=openai))
Read moreShow less
From an equity-investment perspective, the key point is that Athersys is a high-risk, catalyst-driven biotech. The company’s differentiation rests on the potential versatility of its cell-therapy platform, the “off-the-shelf” nature of the product, and the ability to target large unmet medical needs in hospital settings. That said, its market position remains that of a development-stage company competing in a crowded regenerative-medicine landscape, where clinical readouts, regulatory progress, and financing capacity tend to matter more than current revenues. ([athersys.com](https://www.athersys.com/multistem-therapy/clinical-pipeline/default.aspx?LanguageId=1&utm_source=openai))
Athersys also has an international footprint through collaboration and licensing relationships, most notably with Healios in Japan. In 2023, the company announced the licensing of certain animal-health assets to Ardent Animal Health, signaling an effort to monetize non-core assets while preserving focus on the main human-therapy pipeline. This kind of transaction is important for investors because it can help fund clinical development and sharpen strategic priorities. ([athersys.com](https://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Licenses-its-Animal-Health-Assets-to-Ardent-Animal-Health/default.aspx?utm_source=openai))
Recent developments have centered on continued clinical execution and corporate restructuring. In 2023, Athersys highlighted progress in its MATRICS-1 trauma study, ongoing dialogue around its stroke program, and a broader restructuring designed to concentrate resources on existing clinical programs. The company also raised capital through a registered direct offering and private placement, underscoring the typical funding needs of a small-cap biotech. For market participants following SEC Form 4 insider activity, these events frame ATHX as a speculative, binary-outcome name whose value proposition depends on clinical data, partnership monetization, and balance-sheet support. ([athersys.com](https://www.athersys.com/investors/press-releases/press-release-details/2022/Athersys-Announces-Restructuring-and-Management-Changes-to-Focus-on-Its-Existing-Clinical-Programs/default.aspx?utm_source=openai))
